1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
65F8B33E67A2DE8BE85256E86004F7045
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/clinical-investigator-identification-tools-processes-and-tactics?opendocument
18
19opendocument
2018.205.176.85
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Clinical Operations Clinical Trial Investigators

Clinical Investigator Identification: Tools, Processes and Tactics

DB Image

ID: 4619


Features:

Metrics, Graphics


Pages/Slides: 20


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Study Overview

Competition for the time and attention of clinical investigators is increasing. Pharmaceutical, biotech and CRO executives responsible for identifying investigators for clinical trials will benefit from this 20-page document full of the strategies and tactics used by leading companies.

Key Topics
1) How an efficient and effective database can speed the identification process and lead to higher quality investigators
2) How to leverage multiple resources to find top investigators
3) Tactics used to "grow your own" investigators

Sample Best Practices
1. Develop and grow customer-relationship databases with the names and qualifications of clinical investigators who can help jumpstart a study or entry into a new therapeutic area.
-A team at one pharmaceutical company successfully used a clinical-trials recruitment web site to quickly win investigators interest in a very short amount of time.

2. Draw on past experiences of company staff to broaden knowledge about potential investigators.
-One benchmarking partner uses its marketing staff to rank the prestige of KOLs and its external monitors to provide insights on past performance.

3. Invest time in visiting and prospecting for new investigators and sites that may be contributors to future studies for the company.
-One benchmark company proactively contacts sites without a specific trial in mind for the investigator and contacts all investigators submitting information to the its web site within a certain amount of time even if there is no immediate trial appropriate for them.

Methodology
This research originated from a Best Practices, LLC consulting project. It was conducted for a pharmaceutical client and was based on interviews and surveys with pharmaceutical, CRO and investigative site benchmark partners.


Industries Profiled:
Pharmaceutical; Research; Biotech; Medical Device


Companies Profiled:
AAI Development; Amgen; AstraZeneca; Bristol-Myers Squibb; Covance; Lilly; GlaxoSmithKline; ICON; Janssen; PPD; Baxter Healthcare

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.